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M A J O R A R T I C L E
Cost-Effectiveness of Adult Circumcision
in a Resource-Rich Setting for HIV Prevention
among Men Who Have Sex with Men
Jonathan Anderson,1 David Wilson,1 David J. Templeton,1,2 Andrew Grulich,1 Robert Carter,3 and John Kaldor1
1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, 2Sexual Health Department,
Royal Prince Alfred Hospital, Sydney, and 3Deakin Health Economics, Deakin University, Melbourne, Australia
Background. We examined the effects and cost-effectiveness of 4 strategies of circumcision in a resource-rich
setting (Australia) in a population of men who have sex with men (MSM).
Method. We created a dynamic mathematical transmission model and performed an economic analysis to
estimate the costs, outcomes, and cost-effectiveness of different strategies, compared with those of the status quo.
Strategies included circumcision of all MSM at age 18 years, circumcision of all MSM aged 35–44 years, circumcision
of all insertive MSM aged 18 years, and circumcision of all MSM aged 18 years . All costs are reported in US
dollars, with a cost-effectiveness threshold of $42,000 per quality-adjusted life-year.
Results. We find that 2%–5% of human immunodeficiency virus (HIV) infections would be averted per year,
with initial costs ranging from $3.6 million to $95.1 million, depending on the strategy. The number of circumcisions
needed to prevent 1 HIV infection would range from 118 through 338. Circumcision of predominately insertive
MSM would save $21.7 million over 25 years with a $62.2 million investment. Strategies to circumcise 100% of
all MSM and to circumcise MSM aged 35–44 years would be cost-effective; the latter would require a smaller
investment. The least cost-effective approach is circumcision of young MSM close to their sexual debut. Results
are very sensitive to assumptions about the cost of circumcision, the efficacy of circumcision, sexual preferences,
and behavioral disinhibition.
Conclusions. Circumcision of adult MSM may be cost-effective in this resource-rich setting. However, the
intervention costs are high relative to the costs spent on other HIV prevention programs.
The incidence of human immunodeficiency virus
(HIV) infection among men who have sex with men
(MSM) has been increasing in many high-income
countries, including Australia, over the past decade [1].
The increase in HIV infections has prompted interest
in new prevention technologies, along with renewed
interest in prevention and education programs.
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Adult male circumcision has been shown to be ef-
fective for the prevention of HIV acquisition in 3 ran-
domized trials among heterosexual men in Southern
and Eastern Africa [2–4]. A meta-analysis of observa-
tional data on the effect of circumcision among MSM
revealed insufficient recent evidence that male circum-
cision protects against HIV infection or other sexually
transmitted infections, but this meta-analysis did report
an association between circumcision and protection
against HIV infection in studies of MSM that were
conducted before the introduction of highly active an-
tiretroviral therapy [5]. In 2008, a study of a large Aus-
tralian community-based cohort reported a statistically
significantly reduced risk of HIV seroconversion among
circumcised MSM who predominantly took the inser-
tive role in anal intercourse, with an 85% reduction in
the acquisition of HIV among predominately insertive
MSM and a 95% certainty that the true value was be-
tween 20% and 97% [6].
Cost-effectiveness models for Southern and Eastern
1804 • JID 2009:200 (15 December) • Anderson et al
Figure 1. Schematic diagram of the model population of 180,000 men who have sex with men. HIV, human immunodeficiency virus.
Africa have suggested that circumcision is cost-effective [7–9].
However, there have been no economic evaluations of the value
of adult male circumcision for the prevention of HIV infection
in resource-rich countries that have a relatively high baseline
prevalence of circumcision and an HIV epidemic affecting
mainly MSM. On the other hand, the popularity of pediatric
circumcision has been steadily declining in Australia, from rates
of 80% in the 1960s to !10% in the past decade, and hence
the prevalence of circumcision among adults has also been
decreasing [10].
This study aimed to model the potential costs and benefits,
compared with the status quo, of implementing an adult male
circumcision program for the prevention of HIV infection
among Australian MSM. We also aim to consider the efficiency
of targeting intervention to different groups of MSM in the
event of budgetary constraints. Finally, we explored the impacts
of potential changes in behavior on these estimates.
METHODS
Four main strategies of coverage are considered for imple-
mentation of circumcision; these are compared with the status
quo or no specific intervention, which is defined as neonatal
circumcision that continues at the current rate. The strategies
are labeled as follows: (1) sexual debut, which is defined as
circumcision of all uncircumcised MSM at age 18, because this
approach is being adopted in African circumcision programs;
(2) 35–44-year-olds, which is defined as circumcision of all
uncircumcised MSM aged 35–44 years in the first year of the
program and on entry to the age range thereafter, because this
group has the highest incidence of HIV infection in Australia
[1] (their baseline circumcision prevalence is 70% [10]); (3)
insertive, which is defined as circumcision of all MSM aged
18 years who are predominately insertive in their sexual be-
havior, because circumcision is likely to have the greatest effect
in this group; and (4) all MSM, which is defined as circumcision
of all MSM aged 18 years. Each strategy is assumed to start
with an intensive phase during the first year in which all men
in the target group are circumcised and then to continue with
an ongoing program to maintain circumcision rates for indi-
viduals entering the targeted age group each year.
We used a dynamic population-level mathematical transmis-
sion model composed of mathematical differential equations de-
veloped, implemented, and solved with Matlab software (Math-
Works) to estimate the number of new HIV infections over a
25-year period starting in 2008 for each strategy in a hypothetical
population of 180,000 MSM in Australia [11] (Figure 1). The
data on the number of new infections and circumcisions are
included in an economic analysis of costs and benefits that was
performed from the perspective of the government as a third-
party payer. The discounting of costs and outcomes (3%) is
consistent with the policy set by the Panel on Cost-Effectiveness
in Health and Medicine [12]. Costs are reported in US dollars
(2007 prices) with purchasing power parity of 1.43 Australian
dollars equal to 1 US dollar [13].
Our model includes data from previous studies of MSM in
Australia on age-specific circumcision status (range, 50% for
MSM aged 18–25 years to 83% for MSM aged 45 years) [10,
14–16] and HIV prevalence (range, 0.5% for MSM aged 18–
25 years to 18% for MSM aged 45 years) [11]; probability
of HIV acquisition and transmission for different sexual acts
(0.008 for receptive anal sex and 0.0008 for insertive anal sex)
[17–19]; frequency of sexual acts (125 acts per man per year)
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Table 1. Parameters and Values Used in the Mathematical Model
Parameter Value Sensitivity, % Reference(s)
Population 180,000 … [11]
Effectiveness of circumcision in prevention
of HIV acquisition among insertive men, % 60 43–80 [2–4, 32]
Age-specific baseline circumcision status, % [10, 14–16]
!25-Year-olds 50.3 …
25–34-Year-olds 59.3 …
35–44-Year-olds 69.5 …
45-Year-olds 82.6 …
HIV infection prevalence, % [11]
!25-Year-olds 0.5 1.5
25–34-Year-olds 5 6
35–44-Year-olds 10 12
45-Year-olds 18 20
Probability of acquisition [17–19]
Insertive anal 0.0008 …
Receptive anal 0.008 …
Frequency of sexual acts, acts/man/year 125 … [20, 21]
Condom usage, % 65 70 [22, 23]
Condom efficacy, % 90 95 [24, 25]
Use and impact of ART on infectiousness, % [22, 26–29]
HIV-infected MSM on ART 70–75 …
MSM on ART who achieve viral suppression 80 …
Reduction in infectiousness if viral suppression is achieved 95 90
Strategic positioning and role preference, % [6, 30]
Insertive only 33 …
Receptive only 10 …
Insertive and receptive 57 …
Cost of HIV management (discounted) $342,916 $171,328–$513,986 [38]
Cost of intervention circumcision $1,767 $883–$2,365 [36–38]
Utility loss due to HIV, QALYs (discounted) 7.5 … [40]
Discount rate, % 3 0–5 [12]
NOTE. Results of the sensitivity analyses are given as percentages except where otherwise indicated. Costs are given in US dollars.
QALY, quality-adjusted life-year.
[20, 21]; condom usage (65%) [22, 23] and efficacy (90%) [24,
25]; use and impact on infectiousness of antiretroviral therapy
(70%–75% of HIV-infected MSM receive antiretroviral therapy,
of whom 80% achieve viral suppression, which reduces infec-
tiousness by 95%) [22, 26–29]; and strategic positioning and
role preference (33% of MSM engage only in insertive anal sex)
[30]. The model was calibrated to accurately reflect the pop-
ulation of Australian MSM and the HIV epidemic in this pop-
ulation [11]. The simulations used the model input ranges and
adjusted the per-act transmission probabilities (to the levels
indicated above) to produce estimates of HIV infection inci-
dence (mean, 680 cases per year [95% confidence interval {CI},
456–963 cases per year]) that matched the HIV epidemic in
Australia (681 HIV infection diagnoses in the MSM population
in 2006). We assume sexual mixing occurs across all age groups
but is primarily assortative within each age group, with 75%
of sexual episodes occurring between men in the same age
group [31].
Circumcision is assumed to have an effectiveness of 60%,
on the basis of data from 3 randomized controlled trials among
heterosexual men in Southern and Eastern Africa [2–4], with
sensitivity analyses for a range from 40% to 80% to illustrate
the impact of our assumption and the results of a published
meta-analysis [32]. The putative direct benefit of circumcision
would be only to men practicing insertive sex. In the Health
in Men cohort, reported sexual behaviors correlated well with
the initial declared preference [6]. Input values, ranges, and
sources are reported in Table 1. Costs are reported in Table 2.
We define the probability of HIV acquisition per unprotected
penetrative insertive penile-anal act to be for an uncircum-ubi
cised man and for a circumcised man. If is the effectivenessc cb i i
of circumcision in reducing HIV acquisition per insertive act,
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Table 2. Costs of Intervention Circumcision
Procedural item
Patients,
%
Unit cost,
US$
Total cost,
US$
MBS item
or reference
Consultation with GP, with rebate 100 43.57 43.57 36
Test for HIV antibodies 100 9.37 9.37 69384
Consultation with GP, with rebate 100 43.57 43.57 36
Full blood estimate 100 4.76 4.76 65060
Clotting studies 100 8.36 8.36 65120
Chemistry 100 11.78 11.78 66515
Consultation with counselor 100 20.98 20.98 10994
Consultation with specialist, with rebate 100 81.05 81.05 110
Surgery 100 1,403.50 1,403.50 Code M05Z [35]
Consultation with GP for pain 0.30 22.94 0.07 [36, 37]
Consultation with GP for bleeding 2.40 22.94 0.55 [36, 37]
Consultation with GP for infection 3 22.94 0.69 [36, 37]
Consultation with specialist for bleeding 2 40.56 0.81 [36, 37]
Postoperative consultation with surgeon 100 40.56 40.56 116
Consultation with GP to check healing before resuming sex 100 22.94 22.94 23
Consultation with counselor about importance of safe sex 100 20.98 20.98 10994
Consultation with GP, with rebate 100 43.57 43.57 36
Test for HIV antibodies 100 9.37 9.37 69384
Total … … 1,766.46 …
NOTE. Procedural items are given in sequential order; some procedures are repeated. We assume that each procedural item in the
sequence occurs once. GP, general practitioner; HIV, human immunodeficiency virus; MBS, Medical Benefits Schedule of the Australian
Health Insurance Commission.
then . We define the probability of HIV ac-c c ub p (1  )bi i i
quisition per unprotected penetrative receptive penile-anal act
to be for both circumcised and uncircumcised men. Webr
assume that condoms have a protective effectiveness of forc
both insertive and receptive penile-anal sex and for both cir-
cumcised and uncircumcised men, which leads to a probability
of transmission of if a condom is used. If HIV-neg-(1  )bc
ative MSM have an average of n penetrative penile-anal acts
per year, and if condoms are used in a proportion of receptiverpc
acts and of receptive acts, then the probability that a cir-ipc
cumcised man (in age group k) who practices both insertive
and receptive penile-anal sex will acquire HIV each year is
i ic c n 1p 1p c n 1p p( )( ) ( )k,j r c k,j r c( ) ( )l p P 1 1 b 1 1  b[ ] {k j i c i
j
r rn p 1p n p p( )k,j r c k,j r c( ) ( ) 1 b 1 1  b ,[ ] }r c r
where represents the proportion of all acts that are receptive.pr
The probability that an uncircumcised man (in age group k)
who practices both insertive and receptive penile-anal sex will
acquire HIV each year is
i iU u n 1p 1p u n 1p p( )( ) ( )k,j r u k,j r u( ) ( )l p P 1 1 b 1 1  b[ ] {k j i c i
j
r rn p 1p n p p( )k,j r u k,j r u( ) ( ) 1 b 1 1  b .[ ] }r c r
In both cases, denotes the prevalence of HIV infection inPj
sexual partners of age group j, and we use the standard binomial
modeling formula [33, 34], adjusted to include the different
protection options. For men who practice only receptive sex,
the probability of HIV acquisition each year is
r rR n 1p n p( )k,j c k,j c( ) ( )l p P 1 1 b 1 1  b ,[ ]k j r c r{ }
j
and the probability of HIV acquisition per year for men who
practice only insertive sex is
i iIC c n 1p c n p( )k,j c k,j c( ) ( )l p P 1 1 b 1 1  b[ ]k j i c i{ }
j
for circumcised men and
i iIU u n 1p u n p( )k,j u k,j u( ) ( )l p P 1 1 b 1 1  b .[ ]k j i c i{ }
j
for uncircumcised men.
If is the proportion of men in age group k who are cir-ak
cumcised and is the number of men in age group k, thenNk
the expected average number of HIV infections in year t is
IC R C( ) ( ) ( ) ( )I t p a t N 1 P q l + q l + 1 q  q l[ ] k k k I k R k R I k
k
IU R U( ) ( ) ( )+ 1a t N 1 P q l + q l + 1 q  q l ,[ ] [ ]k k k I k R k R I k
where is the proportion of men who engage only in insertiveqI
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Figure 2. Expected number of human immunodeficiency virus (HIV) infections per year among Australian men who have sex with men (MSM),
according to our population-level mathematical transmission model, for the status quo (no intervention) and for strategies of circumcising 100% of
MSM prior to sexual debut, circumcising 100% of 35–44-year-old (yo) MSM, circumcising 100% of MSM who practice only insertive penile-anal sex,
and circumcising all MSM. Curves show mean trajectories of 1000 model simulations.
Figure 3. Number of circumcisions needed to prevent 1 human im-
munodeficiency virus infection for the strategies targeting men who have
sex with men (MSM) prior to sexual debut, 35–44-year-old (yo) MSM,
MSM who practice insertive penile-anal sex, and all MSM.
sex and is the proportion of men who engage only in re-qR
ceptive sex (thus, is the proportion of MSM who1 q  qI R
practice both insertive and receptive sex).
The prevalence of circumcision among Australian men is
nonuniformly distributed across age groups, as presented in
Table 1 [16]. Because the distribution of circumcision rates is
age dependent, the distribution of circumcision with age will
change each year. The proportion of men in age group k who
are circumcised is adjusted each year according to the formula
Dt  1 Nk k1( ) ( ) ( ) ( )a t + 1 p a t + a t + j t ,k k k1 k
Dt N Dtk k k1
where is the “length” in years of age group k andDt j (t)k k
represents specific intervention circumcisions in year t to age
group k. All parameter values used in our mathematical model
are presented in Table 1.
Interventions based on focused circumcisions are simulated,
and the outputs from the model include the number of HIV
infections over time for each strategy. A detailed uncertainty
analysis is performed for each strategy, whereby all input pa-
rameters are specified over a plausible range, and 1000 sets of
parameter values are sampled and used in 1000 model simu-
lations, producing a range of possible values for all outcome
variables.
The population model was developed using inputs relevant
to the Australian setting. To assess the outputs of the model,
we compare the number of HIV infections in the first year of
the model with Australian national surveillance data of HIV
infection diagnoses in the year 2007. Although diagnosis may
lag infection by a number of years, MSM in Australia have
good access to free testing, so this assumption is likely to be
reasonable, especially because the proportion of undiagnosed
HIV infections has been estimated to be relatively low [35].
The economic analyses are performed using Excel software
(Microsoft). Inputs include the number of circumcisions; the
number of HIV infections for each strategy (from the trans-
mission model); the cost of circumcision, including the cost of
the operation [36] and the cost of medical visits for adverse-
effect management and prevention counseling [37, 38], which
are all derived from published cost estimates; the lifetime cost
of management of HIV infection (discounted at 3%) [39]; and
the lifetime loss of quality-adjusted life-years (QALYs) due to
HIV infection (discounted at 3%) [40]. In the analysis, each
incident HIV infection accrued a QALY loss and the cost of
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Table 3. Discounted Incremental Cost-Effectiveness Ratios
Strategy
HIV infections
averteda
QALYs
gaineda
Incremental
cost, US$a
Incremental
cost per QALY
gained, US$
Upper 95%
confidence limit,
US$/QALY
Sexual debut 146 1093 29,332,093 26,841 94,991
35–44-Year-olds 204 1527 14,335,127 9,390 44,332
Insertive 246 1845 21,761,545 Cost-saving Cost-saving
All MSM 444 3328 25,760,458 7,741 18,224
NOTE. Costs are given in US dollars. HIV, human immunodeficiency virus; MSM, men who have sex with
men; QALY, quality-adjusted life-year.
a Discounted.
HIV care; both cost and QALY loss are discounted amounts
that are discounted again at the time in the model that the
infection is assumed to occur. The time horizon of the eco-
nomic analysis is 25 years in 1-year cycles.
The costs (intervention and disease-related costs) and out-
comes (HIV infections and QALYs) are estimated and the in-
cremental cost-effectiveness ratios (ICER) are calculated by
comparing the net costs and net outcomes of each strategy with
the status quo. We assume that a strategy is cost-effective com-
pared with the status quo when the ICER is !$42,000 (equiv-
alent to A$60,000) per QALY gained, which is a shadow price
used in a government-published economic analysis of public-
sector interventions, including HIV-related interventions [41].
For each strategy, we entered the 95% CIs for the number
of HIV infections from the results of the population model
into the Excel spreadsheet used for the economic analyses and
then ran 2000 simulations and compared them with the sta-
tus quo by means of the @Risk software program (Palisade).
We report 95% CIs and probabilities that the ICER will be
less than the cost-effectiveness threshold of $42,000 per QALY
or !0, and simulations with a loss of QALYs counted as
dominated.
We performed 1-way sensitivity analyses to account for other
important model assumptions and uncertainties in the input
parameters, including the impact of risk disinhibition. For var-
iables without a range of published estimates, the ranges for
the sensitivity analyses represent our judgement of the varia-
tions likely to be encountered in the implementation of the
intervention. In the baseline analysis, we included the costs of
the management of postoperative complications of circumci-
sion; in a sensitivity analysis, we also included a 10% loss of
quality of life in a 4-week postoperative period, which was
extrapolated from the literature on quality of life in men with
erectile dysfunction [42]. We also explored the inclusion of
program costs such as marketing, administration, monitoring,
and evaluation.
RESULTS
Over the 25-year period of the population model and compared
with the status quo, there were 241 (1.4%) fewer infections
with the strategy of ensuring that all MSM are circumcised
prior to sexual debut (sexual debut strategy), 318 (1.8%) fewer
infections with the strategy of circumcising all men in the 35–
44-year-old age group (35–44-year-olds), 363 (2.0%) fewer in-
fections in the strategy of circumcising men who practice pre-
dominantly insertive penile-anal sex (insertive strategy), and
655 (3.7%) fewer infections in the strategy of circumcising all
MSM (all MSM strategy). Our model indicates that, after 25
years, 3%–5% of HIV infections per year would be averted
(Figure 2). In the insertive strategy, 118 circumcisions would
be required to prevent 1 HIV infection, and in the all MSM
strategy, 338 of the circumcisions would prevent 1 HIV infec-
tion (Figure 3). We found that 10–27 quality-adjusted days
(undiscounted) would be gained per circumcision performed,
depending on the strategy. The expected change in incidence
due to any of the intervention circumcisions is relatively mod-
est, and thus the overall prevalence was not found to change
substantially over 25 years as a result of circumcision (a max-
imum change of 0.15% in absolute prevalence).
Circumcision and medical costs for the first year of the in-
tervention would be $3.6 million for the sexual debut strategy,
$20.6 million for the strategy targeting 35–44-year-old MSM,
$33.3 million for the strategy targeting insertive MSM, and
$95.1 million for the all MSM strategy. Once the initial startup
phase had passed, the yearly costs would range from $2.0 mil-
lion to $5.5 million.
The insertive strategy would save $21.7 million over 25 years,
compared with the status quo, for an overall investment of
$62.2 million (discounted), with 2% likelihood that it would
not be cost-saving and a 0.4% likelihood of not being cost-
effective. All other strategies would be cost-effective with an
ICER of !$42,000 (A$60,000) per QALY gained (Table 3), with
1% likelihood that the all MSM strategy would not be cost-
effective, but with a 3.6% and 25% likelihood that the 35–44
year old and sexual debut strategies, respectively, would not be
cost-effective. The insertive strategy was cost-effective after 7
years of the model, whereas the sexual debut strategy proceeded
for 21 years until becoming cost-effective. The total investment
over 25 years for the 35–44 year old strategy would be $83.9
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Figure 4. Tornado plot of the impact of varying the input parameters on the incremental cost-effectiveness ratio (ICER) of the strategy of circumcising
all men who have sex with men. HIV, human immunodeficiency virus; QALY, quality-adjusted life-year.
million (discounted), and that for the all MSM strategy would
be $177.6 million.
If men who have been circumcised as part of the intervention
reduce their use of condoms by 10%, then none of the inter-
ventions are effective, and therefore, none could be cost-effec-
tive. If only 80% of all MSM are circumcised, the intervention
costs $14,700 per QALY, and if 90% of all MSM are circumcised,
the intervention costs $9,000 per QALY.
The results of sensitivity analyses of cost and discounting are
presented in Figure 4 for the all MSM strategy. The results are
similar for the other strategies (not shown). The model is most
sensitive to the effectiveness of circumcision, the proportion of
predominately insertive men, and the costs of circumcision and
of the management of HIV infection: the intervention is cost-
saving for all strategies if circumcision is 50% cheaper, it re-
mains cost-effective for 3 of the 4 strategies if the cost doubles
due to program and marketing costs, and it would remain cost-
effective in most scenarios if HIV infection in Australia cost
50% less than the baseline assumption. The ICER is less affect-
ed by the discount rate. If men being circumcised have a tempo-
rary loss of quality of life, then there is little effect on cost-
effectiveness (Figure 4).
DISCUSSION
This study explores the cost-effectiveness of circumcision as a
technology to prevent HIV infection in MSM in a resource-
rich setting. Our model suggests that a range of different strat-
egies to implement circumcision could be cost-effective or cost-
saving as an intervention to prevent the spread of HIV among
MSM. The investment required for a circumcision program
would be considerable for its limited impact on the epidemic.
However, the effectiveness of circumcision could be nullified
if it leads to increases in risk behavior, which is a plausible
outcome.
An estimated one-third of the MSM in Sydney predomi-
nantly take the insertive role in anal intercourse [6]. Circum-
cision of predominately insertive MSM would save $21.7 mil-
lion over 25 years with a $62.2 million investment. However,
our model assumes that the sexual preferences of MSM would
remain stable over 25 years. This assumption is contestable,
because sexual behavior and preference may depend on emo-
tions, setting, partnership dynamics, age, and culture and hence
be fluid in the long run.
Globally, circumcision programs to prevent HIV infection
are being targeted at young men, on the basis of data from
randomized controlled trials in Africa on effectiveness [2–4,
32] and cost-effectiveness [7, 8]. In our model, circumcision
of young men close to sexual debut was the least cost-effective
strategy. The implementation of the sexual debut strategy could
also pose significant challenges because of difficulties in iden-
tifying large numbers of young MSM early in their sexual lives.
Circumcision of men in the age group with the highest inci-
dence of HIV infection in Australia (35–44 years old) [1] was
almost as cost-effective as circumcision of all MSM, but the
former strategy involved a much smaller initial investment. If
circumcision were to be adopted as a public health intervention
in Australia, our study suggests that the intervention would be
best targeted at this age group.
The scale and effectiveness of a circumcision program could
be limited by resource constraints and fiscal burden [43]. In
Australia, adult male circumcision is currently usually per-
formed by a surgeon as a day case or with an overnight hospital
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stay. Hospitals have significantly long waiting lists because of
limited human and other resources, especially in regional and
remote settings. Primary care practitioners would require extra
training to perform the procedure and funding for higher levels
of indemnity insurance. Australian federal and state govern-
ments spend different amounts of money on HIV prevention
and education campaigns, but none exceed $7 million per year
[44]. The likelihood that governments would decide to invest
a large amount of money in a single prevention technology is
low.
One could argue that a focus on circumcision might also
reduce the funding and attention that is available to other cost-
effective programs to prevent the spread both of HIV and of
other diseases [45] and might have other negative externalities.
For example, our model showed that a 10% decrease in the
level of condom use would render the intervention ineffective.
However, there was no evidence of disinhibition among par-
ticipants in the African randomized trials [46].
Circumcision is a unique prevention intervention: it is de-
livered only once; requires no further adherence, cognition, or
purchases; and is present at every sexual encounter for the
lifetime of the individual. But the impact of circumcision was
estimated to be low in the population of MSM; circumcision
averted only 2%–5% of HIV infections in our model. Preven-
tion of 1 HIV infection would require 118–338 circumcisions,
a substantially higher number than the estimated 72 circum-
cisions required to prevent 1 HIV infection among African
heterosexual men [32].
In our model, we assumed that all members of the population
would accept circumcision and would have equal access to
health services. However, acceptance of circumcision may be
reduced by personal and cultural beliefs. Although there are
no data on Australian MSM, a study from the United States
suggested that MSM would consider adult circumcision if it
reduced sexual transmission of HIV [47]. Men may believe that
sexual pleasure is reduced without a foreskin, despite evidence
to the contrary from the African setting.
The analyses of the uncertainty related to the population
model inputs suggest that there is only a 75% likelihood that
a strategy of circumcising young MSM would be cost-effective,
although there was less uncertainty about the cost-effectiveness
of a strategy of circumcising all MSM. Lower levels of coverage
for the all MSM strategy would still be cost-effective and would
have smaller initial budget impacts. The 1-way sensitivity anal-
yses also demonstrate that the results are very sensitive to as-
sumptions about the effectiveness of circumcision, the pro-
portion of men who are predominately insertive, and the costs
of circumcision and HIV-related health care.
Our study had a number of limitations. First, models are
only approximations of the real world, and simplifying as-
sumptions must be made. For example, there are no data avail-
able on the degree of assortative-disassortive mixing across age
groups; we used estimates consistent with a recent modeling
study that estimated mixing patterns across age groups of Aus-
tralian MSM [31]. Second, we used the efficacy of circumcision
that was determined from the randomized controlled trials in-
volving heterosexual men in Southern and Eastern Africa [2–
4]. However, this estimate fell within the CIs of the estimated
reduction of HIV risk that was conferred by circumcision in a
large prospective study involving MSM [6]. Third, we used
estimates of the discounted QALYs lost and of the costs as-
sociated with a lifetime of HIV infection, but these were derived
and valued in the United States, which has a health system that
is very different from the health system in Australia [40]. How-
ever, the cost estimates used in our model were consistent with
the costs of HIV-related health care that were derived using an
activity-based approach with local costs and data in an Aus-
tralian economic evaluation of needle and syringe programs
[48]. Finally, we did not consider the potential additional ben-
efits associated with circumcision in the reduction of other
sexually transmitted infections, which may have underesti-
mated the potential benefits.
In conclusion, our study is the first cost-effectiveness analysis
of adult male circumcision among MSM and uses data from
rigorously conducted studies in the population. We showed that
circumcision could be cost-effective and even cost-saving for
a range of implementation strategies. However, the investment
required would be considerable, and the impact on the overall
epidemic would be limited. In addition, if a perception of being
protected from HIV led to increased HIV risk behavior, then
the effectiveness of the intervention could easily be overcome.
In such a setting, it is not inconceivable that the intervention
could lead to an increase rather than a decrease in new HIV
infections. A single technology such as circumcision is unlikely
to be effective in a complex epidemic; combinations of new
and classical health promotion actions are likely to be needed
[49].
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